Invesco Ltd. Sells 49,367 Shares of Enhabit, Inc. $EHAB

Invesco Ltd. reduced its position in Enhabit, Inc. (NYSE:EHAB) by 17.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,309 shares of the company’s stock after selling 49,367 shares during the quarter. Invesco Ltd. owned 0.47% of Enhabit worth $2,086,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in EHAB. D. E. Shaw & Co. Inc. raised its holdings in shares of Enhabit by 33.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,004,215 shares of the company’s stock valued at $7,843,000 after acquiring an additional 250,215 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Enhabit by 12.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,953,941 shares of the company’s stock valued at $15,260,000 after acquiring an additional 213,774 shares in the last quarter. Systematic Financial Management LP raised its holdings in shares of Enhabit by 8.6% in the fourth quarter. Systematic Financial Management LP now owns 1,996,113 shares of the company’s stock valued at $15,590,000 after acquiring an additional 157,914 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in shares of Enhabit by 95.5% in the fourth quarter. Nuveen Asset Management LLC now owns 265,361 shares of the company’s stock valued at $2,072,000 after acquiring an additional 129,610 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new stake in shares of Enhabit in the fourth quarter valued at about $601,000.

Analysts Set New Price Targets

Separately, UBS Group reduced their target price on shares of Enhabit from $10.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 8th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Enhabit has an average rating of “Hold” and a consensus price target of $8.67.

Insider Buying and Selling at Enhabit

In other Enhabit news, CFO Ryan Solomon purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $7.64 per share, for a total transaction of $76,400.00. Following the completion of the purchase, the chief financial officer owned 193,468 shares of the company’s stock, valued at approximately $1,478,095.52. The trade was a 5.45% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 3.40% of the company’s stock.

Enhabit Price Performance

Shares of EHAB stock opened at $7.90 on Friday. Enhabit, Inc. has a fifty-two week low of $6.47 and a fifty-two week high of $10.90. The firm has a market capitalization of $400.20 million, a price-to-earnings ratio of -2.96 and a beta of 1.68. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.57 and a current ratio of 1.57. The stock’s 50-day simple moving average is $7.57 and its 200-day simple moving average is $8.48.

Enhabit (NYSE:EHAB) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.03. Enhabit had a positive return on equity of 2.72% and a negative net margin of 12.84%.The business had revenue of $266.10 million for the quarter, compared to analyst estimates of $263.39 million. As a group, equities analysts forecast that Enhabit, Inc. will post 0.22 earnings per share for the current fiscal year.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.